Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN0191 Phase 1 in Elevated LDL-C
NCT05905068Phase 1Completed
- Sponsor
- Ikaria
- Start
- Jul 2023
- Primary completion
- Feb 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of RN0191 in hypercholesterolemia (5 arms), sponsored by Ikaria. Primary endpoint: Safety and Tolerability at Day 57. Started Jul 2023; status: completed.
02
Drugs
RN0191
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05905068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905068.